Sandoz digital “Scientific Standalone” event will help drive access to medical information in field of cardiovascular therapies

  • Sandoz Scientific Standalone event — “Reach Targets, Save Lives” – aims at increasing access to information in the field of cardiovascular therapies in Central & Eastern Europe and Middle East & Africa (CEEMEA)
  • Lectures by leading cardiologists and internal medicine specialists will be recorded and offered for re-use across the region following the live event
  • Enhanced digital training can help improve health outcomes for patients

 

Holzkirchen, March 20, 2017 – …

/by

Sandoz digital “Scientific Standalone” event will help drive access to medical information in field of cardiovascular therapies

  • Sandoz Scientific Standalone event — “Reach Targets, Save Lives” – aims at increasing access to information in the field of cardiovascular therapies in Central & Eastern Europe and Middle East & Africa (CEEMEA)
  • Lectures by leading cardiologists and internal medicine specialists will be recorded and offered for re-use across the region following the live event
  • Enhanced digital training can help improve health outcomes for patients

 

Holzkirchen, March 20, 2017 – …

/by

Sandoz announces winners of inaugural Healthcare Access Challenge (Sandoz HACk)

  • Three winners, chosen by expert panel at Wired Health 2017 in London, identified innovative approaches to address access challenges in Ghana, the Maldives and the Philippines.
  • Winning ideas proposed novel ways to use mobile technologies to connect patients with caregivers and essential medicines
  • Sandoz invited young people worldwide to “reimagine access to healthcare” – arguably the largest unmet medical need

London, March 13, 2017 – Sandoz, a Novartis Division, announced today the three winners of the inaugural Healthcare …

/by

New data demonstrate Sandoz proposed biosimilar adalimumab has equivalent efficacy to reference medicine

  • Sandoz proposed biosimilar adalimumab (GP2017) shown to have equivalent efficacy and a similar safety profile as reference medicine, Humira®*
  • Comprehensive development program show potential of GP2017 to treat inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis
  • Study reinforces strength of Sandoz pipeline and its key role in the broader Novartis immunology portfolio

Holzkirchen, 6 March 2017 – Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today …

/by